Clinical Trial

Intratumoral Injection of IP-001 Following Thermal Ablation in Patients With CRC, NSCLC, and STS

Study acronym: INJECTABL-1
Active, Not Recruiting Phase 1/2
View on ClinicalTrials.gov →
Record status
This record was last updated January 8, 2025 (before its estimated February 2025 completion). Its status may not reflect the trial's current state.
Summary
The goal of this clinical trial is to determine the safety and efficacy of IP-001 for intratumoral injection administration following thermal ablation of a solid tumor.
Protocol Amendment History 6 amendments
This ClinicalTrials.gov record has been amended 6 times since 2023-01-08; most recent amendment 2025-01-07.
Status change: Recruiting → Active, Not Recruiting 2025-01-07
Trial Details
NCT Number NCT05688280
Lead Sponsor Immunophotonics, Inc.
Conditions Metastatic Solid Tumor, Colon Cancer, Nonsmall Cell Lung Cancer, Soft Tissue Sarcoma
Enrollment 42 participants
Start Date 2022-11-29
Primary Completion 2025-02 (estimated)
Study Completion 2025-02 (estimated)
Updated on ClinicalTrials.gov 2025-01-08